Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2022 Financial and Operational Results
SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
Enterprise Connect 2024 Takes Place March 25-28 in Orlando, FL SAN FRANCISCO–(BUSINESS WIRE)–Enterprise Connect, the…
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31,…
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue…
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery…
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with…
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b…
All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months…
Fortress expects to file a total of three new drug applications in 2023 Record consolidated…
REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”),…
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May…
Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., March 30,…
Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line…
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line Image: GreenLight Biosciences…
– Full enrollment of the LUNA trial anticipated in the second half of 2023 –…
– FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and…
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial…
DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target…